NLRP3 is upregulated in a number of cancers, including head-and-neck, gastric, lung, kidney, melanoma, and myelodysplasia, and it often drives cancer progression and immunosuppression, correlating with poor patient outcomes [23, 24]. Here, NLRP3 is linked to cancer.